8-KOther Events

BRISTOL MYERS SQUIBB CO 8-K Report (Sep 19, 2001)

Filed September 19, 2001For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) has announced a significant strategic partnership with ImClone Systems Incorporated. This collaboration focuses on the co-development and co-promotion of a promising cancer drug within the United States, Canada, and Japan. This move signals BMY's commitment to expanding its oncology pipeline and leveraging external innovation to address critical unmet medical needs in cancer treatment. In addition to the co-development agreement, Bristol-Myers Squibb intends to acquire a substantial minority stake in ImClone Systems, representing approximately 19.9% of the company's outstanding shares through a tender offer. This acquisition underscores BMY's confidence in ImClone's technology and the potential of the partnered drug, offering investors a clear indication of the company's strategic direction in the competitive pharmaceutical landscape.

Key Highlights

  • 1Bristol-Myers Squibb (BMY) enters into a co-development and co-promotion agreement with ImClone Systems Incorporated for a cancer drug.
  • 2The agreement covers the United States, Canada, and Japan markets.
  • 3BMY plans to acquire approximately 19.9% of ImClone Systems' outstanding shares via a tender offer.
  • 4This partnership highlights BMY's strategic focus on expanding its oncology portfolio.
  • 5The agreement signifies a commitment to advancing cancer treatments through collaboration and investment.
  • 6This 8-K filing primarily reports on the announcement of these strategic transactions.

Frequently Asked Questions

The primary announcement in this filing is that Bristol-Myers Squibb has reached an agreement with ImClone Systems Incorporated to co-develop and co-promote a cancer drug and to acquire a significant minority stake in ImClone.

The agreement covers the United States, Canada, and Japan.

Bristol-Myers Squibb intends to acquire approximately 19.9% of the outstanding shares of ImClone Systems through a tender offer.

This deal indicates Bristol-Myers Squibb's strategic focus on strengthening its oncology pipeline by partnering with and investing in promising biotechnology companies like ImClone Systems.